These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1102 related articles for article (PubMed ID: 28652049)

  • 21. The clinical application of 320-detector row CT in transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma.
    Du F; Jiang R; Gu M; He C; Guan J
    Radiol Med; 2015 Aug; 120(8):690-4. PubMed ID: 25698303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reproducibility of mRECIST in Measurement and Response Assessment for Hepatocellular Carcinoma Treated by Transarterial Chemoembolization.
    Choi MH; Park GE; Oh SN; Park MY; Rha SE; Lee YJ; Jung SE; Choi JI
    Acad Radiol; 2018 Nov; 25(11):1363-1373. PubMed ID: 29555570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differences Between CT-Perfusion and Biphasic Contrast-enhanced CT for Detection and Characterization of Hepatocellular Carcinoma: Potential Explanations for Discrepant Cases.
    Perl RM; Portugall J; Hinterleitner C; Hinterleitner M; Kloth C; Walter SS; Bitzer M; Horger MS
    Anticancer Res; 2021 Mar; 41(3):1451-1458. PubMed ID: 33788737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of perfusion CT as a follow-up modality after transcatheter arterial chemoembolization: an experimental study in a rabbit model.
    Choi SH; Chung JW; Kim HC; Baek JH; Park CM; Jun S; Kim MU; Lee ES; Cho HR; Jae HJ; Lee W; Park JH
    Invest Radiol; 2010 Jul; 45(7):427-36. PubMed ID: 20440211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transarterial Chemoembolization of HCC with Radiopaque Microspheres: Evaluation with Computed Tomography and the Complementary Role of Contrast-Enhanced Ultrasonography.
    Moschouris H; Malagari K; Dimakis A; Kiakidis T; Anagnostopoulou A
    Cardiovasc Intervent Radiol; 2020 Jul; 43(7):1075-1083. PubMed ID: 32394087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor Enhancement and Heterogeneity Are Associated With Treatment Response to Drug-Eluting Bead Chemoembolization for Hepatocellular Carcinoma.
    Reis SP; Sutphin PD; Singal AG; Grzybowski R; Fisher S; Ball C; Xi Y; Grewal S; Kalva SP
    J Comput Assist Tomogr; 2017; 41(2):289-293. PubMed ID: 27824665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advanced Hepatocellular Carcinoma: Pretreatment Contrast-enhanced CT Texture Parameters as Predictive Biomarkers of Survival in Patients Treated with Sorafenib.
    Mulé S; Thiefin G; Costentin C; Durot C; Rahmouni A; Luciani A; Hoeffel C
    Radiology; 2018 Aug; 288(2):445-455. PubMed ID: 29584597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of C-arm CT for transcatheter arterial chemoembolization of hepatocellular carcinoma: diagnostic performance and predictive value for therapeutic response compared with gadoxetic acid-enhanced MRI.
    Yu MH; Kim JH; Yoon JH; Kim HC; Chung JW; Han JK; Choi BI
    AJR Am J Roentgenol; 2013 Sep; 201(3):675-83. PubMed ID: 23971463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Value of the portal venous phase in evaluation of treated hepatocellular carcinoma following transcatheter arterial chemoembolisation.
    Lam A; Fernando D; Sirlin CC; Nayyar M; Goodwin SC; Imagawa DK; Lall C
    Clin Radiol; 2017 Nov; 72(11):994.e9-994.e16. PubMed ID: 28779950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Value of texture analysis based on enhanced MRI for predicting an early therapeutic response to transcatheter arterial chemoembolisation combined with high-intensity focused ultrasound treatment in hepatocellular carcinoma.
    Yu JY; Zhang HP; Tang ZY; Zhou J; He XJ; Liu YY; Liu XJ; Guo DJ
    Clin Radiol; 2018 Aug; 73(8):758.e9-758.e18. PubMed ID: 29804627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic Value of Quantitative Perfusion Computed Tomography Technique in the Assessment of Tumor Response to Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
    Ippolito D; Querques G; Pecorelli A; Talei Franzesi C; Okolicsanyi S; Strazzabosco M; Sironi S
    J Comput Assist Tomogr; 2019; 43(2):206-213. PubMed ID: 30407241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histogram Analysis of CT Perfusion of Hepatocellular Carcinoma for Predicting Response to Transarterial Radioembolization: Value of Tumor Heterogeneity Assessment.
    Reiner CS; Gordic S; Puippe G; Morsbach F; Wurnig M; Schaefer N; Veit-Haibach P; Pfammatter T; Alkadhi H
    Cardiovasc Intervent Radiol; 2016 Mar; 39(3):400-8. PubMed ID: 26216725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants.
    Bargellini I; Bozzi E; Campani D; Carrai P; De Simone P; Pollina L; Cioni R; Filipponi F; Bartolozzi C
    Eur J Radiol; 2013 May; 82(5):e212-8. PubMed ID: 23332890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation between tumor perfusion and lipiodol deposition in hepatocellular carcinoma after transarterial chemoembolization.
    Yang L; Zhang XM; Zhou XP; Tang W; Guan YS; Zhai ZH; Dong GL
    J Vasc Interv Radiol; 2010 Dec; 21(12):1841-6. PubMed ID: 20980165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma.
    Vesselle G; Quirier-Leleu C; Velasco S; Charier F; Silvain C; Boucebci S; Ingrand P; Tasu JP
    Eur Radiol; 2016 Jun; 26(6):1640-8. PubMed ID: 26455721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatic arterial and portal venous phase helical CT in patients treated with transcatheter arterial chemoembolization for hepatocellular carcinoma: added value of unenhanced images.
    Kim HC; Kim AY; Han JK; Chung JW; Lee JY; Park JH; Choi BI
    Radiology; 2002 Dec; 225(3):773-80. PubMed ID: 12461260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Study on the changes of CT texture parameters before and after HCC treatment in the efficacy evaluation and survival predication of patients with HCC.
    Zhou W; Lv Y; Hu X; Luo Y; Li J; Zhu H; Hai Y
    Front Oncol; 2022; 12():957737. PubMed ID: 36387217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parametric response mapping cut-off values that predict survival of hepatocellular carcinoma patients after TACE.
    Nörthen A; Asendorf T; Shin HO; Hinrichs JB; Werncke T; Vogel A; Kirstein MM; Wacker FK; Rodt T
    Abdom Radiol (NY); 2018 Dec; 43(12):3288-3300. PubMed ID: 29680967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Applying arterial enhancement fraction (AEF) texture features to predict the tumor response in hepatocellular carcinoma (HCC) treated with Transarterial chemoembolization (TACE).
    Mao X; Guo Y; Wen F; Liang H; Sun W; Lu Z
    Cancer Imaging; 2021 Aug; 21(1):49. PubMed ID: 34384496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. mRECIST criteria and contrast-enhanced US for the assessment of the response of hepatocellular carcinoma to transarterial chemoembolization.
    Moschouris H; Malagari K; Papadaki MG; Kornezos I; Stamatiou K; Anagnostopoulos A; Chatzimichael K; Kelekis N
    Diagn Interv Radiol; 2014; 20(2):136-42. PubMed ID: 24317334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.